Ultragenyx Pharmaceutical Inc. (RARE) News
Filter RARE News Items
RARE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RARE News Highlights
- For RARE, its 30 day story count is now at 3.
- Over the past 18 days, the trend for RARE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about RARE are DRUG and EC.
Latest RARE News From Around the Web
Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.
Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultrarare, inherited form of high cholesterolTORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza® (evinacumab) in Canada. Evkeeza® was |
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NOVATO, Calif., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 33,475 restricted stock units of the company’s common stock to 10 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Empl |
Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ...Unpacking the Risks and Rewards |
Ultragenyx to Participate at Investor Conferences in SeptemberCiti BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will participate in a panel discus |
Henrietta Lacks' family sues Ultragenyx over use of HeLa cell lineThe estate of Henrietta Lacks filed a lawsuit in Maryland federal court on Thursday accusing biopharmaceutical company Ultragenyx Pharmaceutical of unlawfully profiting from cells that were taken from Lacks' body without her consent during a medical procedure in 1951. The lawsuit said that Novato, California-based Ultragenyx, which develops treatments for rare genetic diseases, uses the famous "HeLa" line of cells "like a dairy farm treats cows" to mass-produce materials for gene therapy. Lacks' estate reached a confidential settlement in a similar lawsuit against laboratory-equipment maker Thermo Fisher earlier this month. |
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value EstimateKey Insights Using the 2 Stage Free Cash Flow to Equity, Ultragenyx Pharmaceutical fair value estimate is US$60.90... |
Q2 2023 Ultragenyx Pharmaceutical Inc Earnings CallQ2 2023 Ultragenyx Pharmaceutical Inc Earnings Call |
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues BeatUltragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track. |
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate UpdateSecond quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a |
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseInitial data expected in first half of 2024NOVATO, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced it has begun dosing the second dose-escalation cohort in its pivotal Phase 1/2/3 Cyprus2+ study following completion of dosing and safety review in the first cohort. The company's investigational AAV9 gene therapy is designed to deliver stable expression of the ATP7B copper transporter following a single intravenous infusion, with the goal of |